Iladatuzumab provides a CD79b-targeting monoclonal antibody for lymphoma, leukemia, and antibody research and specifically recognizes CD79b, a component of the B-cell receptor (BCR) complex expressed on normal and malignant B cells. Iladatuzumab supports studies of B-cell antigen recognition, antibody-mediated targeting, and antibody-drug conjugate (ADC) development.
Key Features and Benefits
- CD79b-Targeting Antibody: Recognizes CD79b, a B-cell surface protein specifically involved in antigen receptor signaling and cellular activation.
- Monoclonal Antibody Platform: Provides an antibody specifically for investigating CD79b recognition and malignant B-cell targeting.
- CD79b Recognition: Supports investigation of CD79b expression, antibody binding, internalization, and antigen-specific cellular interactions.
- B-Cell Receptor Research: Enables studies of CD79b-associated receptor signaling and antibody-mediated cellular responses.
- B-Cell Malignancy Targeting: Supports investigation of antibody binding to CD79b-expressing lymphoma and leukemia cells.
- ADC Development Platform: Provides a targeting antibody platform specifically for investigating CD79b-directed drug conjugation and payload delivery strategies.
- Cellular Internalization Research: Supports investigation of antibody uptake and intracellular trafficking in CD79b-expressing cells.
- Antibody Engineering Research: Especially useful for studying antigen specificity, antibody modification, and targeted delivery approaches.
Applications
- Non-Hodgkin Lymphoma Research: Supports investigation of CD79b-directed antibody targeting in non-Hodgkin lymphoma models.
- Diffuse Large B-Cell Lymphoma Research: Useful for studying CD79b expression and antibody recognition in DLBCL models.
- B-Cell Leukemia Research: Supports evaluation of CD79b-targeting strategies in relevant B-cell leukemia models.
- CD79b-Positive Cancer Research: Enables investigation of antigen expression and antibody interactions in CD79b-expressing malignant cells.
- B-Cell Biology Research: Supports studies of CD79b function, B-cell receptor signaling, and antigen-mediated cellular responses.
- ADC Research: Provides a targeting antibody platform for investigating CD79b-directed payload conjugation and delivery.
- Antibody Binding Assays: Useful for evaluating antigen recognition, binding specificity, and antibody-cell interactions.
- Cellular Internalization Studies: Supports investigation of antibody uptake and intracellular trafficking in CD79b-expressing cells.
- Comparative Antibody Research: Useful for comparing CD79b-targeting antibodies and antibody-mediated B-cell recognition strategies.
Storage and Handling
- Storage: Store according to the product specification under recommended temperature conditions. Protect from excessive heat and repeated freeze-thaw cycles.
- Handling: Handle using appropriate procedures for monoclonal antibody research materials. Maintain conditions that preserve antibody stability, structural integrity, and antigen-binding activity.
Iladatuzumab provides a CD79b-directed monoclonal antibody for investigating B-cell antigen recognition and targeted cellular interactions and specifically supports non-Hodgkin lymphoma, diffuse large B-cell lymphoma, B-cell biology, antibody engineering, and ADC research.
AxisPharm offers 5000+ PEG Linkers with high purity. Different kinds of PEG Reagents may be available by custom synthesis.
